TG Therapeutics prepares to approach regulators with MS drug; Investors bet $93M on a life sciences tools company
Gearing up for a battle with pharma giants, TG Therapeutics says it’s nearly ready to approach regulators with its CD20 drug for multiple sclerosis.
The biotech read out results from two Phase III trials at AAN, which show its candidate ublituximab reduced patients’ annualized relapse rate by 60% and 50% compared to Sanofi’s Aubagio, or teriflunomide — an 8-year-old drug that’s often used as a benchmark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
